73,769 Shares in Amarin Co. plc (NASDAQ:AMRN) Purchased by Gilliland Jeter Wealth Management LLC

Gilliland Jeter Wealth Management LLC bought a new stake in Amarin Co. plc (NASDAQ:AMRN) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 73,769 shares of the biopharmaceutical company’s stock, valued at approximately $64,000.

Other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its position in Amarin by 351.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 34,725 shares in the last quarter. SVB Wealth LLC grew its position in Amarin by 100.0% in the 4th quarter. SVB Wealth LLC now owns 60,000 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 30,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Amarin by 16.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 122,498 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 17,613 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. grew its position in Amarin by 18.9% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 129,200 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 20,500 shares in the last quarter. Finally, Waterfront Wealth Inc. grew its position in Amarin by 18.0% in the 4th quarter. Waterfront Wealth Inc. now owns 386,735 shares of the biopharmaceutical company’s stock valued at $336,000 after acquiring an additional 58,942 shares in the last quarter. 22.25% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Amarin in a research report on Friday, January 12th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $1.08.

Amarin Stock Performance

Shares of AMRN traded up $0.01 during midday trading on Friday, hitting $0.87. The company had a trading volume of 490,768 shares, compared to its average volume of 1,207,184. The company’s 50-day simple moving average is $0.98 and its 200-day simple moving average is $0.93. The firm has a market capitalization of $359.30 million, a P/E ratio of -6.25 and a beta of 1.98. Amarin Co. plc has a 1 year low of $0.65 and a 1 year high of $1.49.

Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.04. The business had revenue of $74.71 million during the quarter, compared to analysts’ expectations of $72.46 million. Amarin had a negative return on equity of 10.47% and a negative net margin of 19.26%. Equities analysts predict that Amarin Co. plc will post -0.14 earnings per share for the current fiscal year.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.